ACHV

Achieve Life Sciences, Inc. (ACHV) - Q2 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2026. Achieve Life Sciences, Inc. is a late-stage clinical specialty pharmaceutical company focused on the development and commercialization of cytisinicline for smoking and vaping cessation. The company has no approved products and has not generated product revenue to date. In June 2026, the FDA issued a Complete Response Letter (CRL) regarding the company's New Drug Application (NDA) for smoking cessation, citing manufacturing-related observations at a third-party facility and labeling issues, though no clinical efficacy or safety deficiencies were noted.

Key Financial Metrics

Note: The significant increase in Net Loss is primarily driven by a $48.5 million unrealized loss on the fair value of warrant liabilities and $8.8 million in warrant issuance costs associated with the April 2026 private placement.

Material Changes vs. Prior Period

• Financing Activity: In April 2026, the company completed a private placement raising approximately $168.2 million in net proceeds. This significantly increased cash and marketable securities from $36.4 million at year-end 2025 to $187.3 million at June 30, 2026.
• Expense Structure: General and Administrative (G&A) expenses increased to $21.8 million (vs. $11.7 million in 2025) due to commercial launch preparation and higher employee expenses (including stock-based compensation). Research and Development (R&D) expenses decreased to $7.1 million (vs. $13.8 million in 2025) as the ORCA-OL clinical trial concluded in September 2025.
• Liabilities: The balance sheet now reflects a substantial $182.7 million warrant liability and $0.7 million pre-funded warrant liability, which were not present in the prior period. These are classified as Level 3 fair value liabilities.
• Leadership Change: Andrew D. Goldberg, M.D., was appointed CEO and President effective April 18, 2026.

Guidance, Outlook, and Risks

• Regulatory Outlook: The company intends to resubmit its NDA in the fourth quarter of 2026, naming Adare Pharma Solutions as the new finished drug product manufacturer to address the FDA's manufacturing observations. Approval for smoking cessation is anticipated in the first half of 2027, followed by a U.S. commercial launch.
• Manufacturing Transition: The company has completed analytical method transfer and an engineering batch at Adare's facility in Vandalia, Ohio, to mitigate supply chain risks and potential tariffs.
• Legal Contingency: The company is involved in an arbitration with Sopharma AD regarding the supply agreement. Sopharma alleges breach of contract due to the company's use of third-party manufacturers. The company disputes these claims; no liability has been recorded as the outcome is uncertain.
• Liquidity Risk: Despite the recent capital raise, the company has a negative working capital balance of $9.4 million due to the classification of warrants as liabilities. Continued funding is required to support commercialization efforts.

Investor Verification Checklist

• Warrant Liability Valuation: Verify the assumptions (volatility, expected life) used in the Black-Scholes model that resulted in the $182.7 million warrant liability, as this significantly impacts reported equity and net loss.
• Manufacturing Qualification: Confirm the status of the FDA pre-approval inspection for the new manufacturer, Adare Pharma Solutions, which is critical for the Q4 2026 NDA resubmission.
• Sopharma Arbitration: Monitor developments in the arbitration with Sopharma, as an unfavorable ruling could restrict manufacturing options or incur significant costs.
• Debt Covenants: Review the covenants of the $15 million SVB convertible debt, specifically the requirement to maintain cash balances at SVB and the conversion triggers.
• Commercial Infrastructure: Assess the progress of hiring and building the commercial team, given the increased G&A spend and the target 2027 launch date.